Fennec Pharmaceuticals Inc.
TSX:FRX.TOBiotechnology
-$0.22 today
- Market cap
- $676.80M
- Beta
- 1.08
- P/E (TTM)
- -36.5
- EPS (TTM)
- -$0.24
Volume 0.00M
Average 0.00M
FRX.TO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Fennec Pharmaceuticals Inc.TSX: FRX.TO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $990K rose 24.1% year over year, behind the +54.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 60.7% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.
Context
- Stock-based compensation amounted to 15.8% of revenue in FY2025, up 5.1 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +24.1% toward the trailing-twelve-month pace of +54.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 7.03M USD
- Year-over-year change
- +39.0%
- 4-year CAGR
- +15.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.03M | +39.0% |
| FY2024 | 2024-12-31 | 5.06M | -5.5% |
| FY2023 | 2023-12-31 | 5.35M | +26.9% |
| FY2022 | 2022-12-31 | 4.22M | +5.1% |
| FY2021 | 2021-12-31 | 4.02M | — |
Stock-Based Compensation vs competitors
How FRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +54.8% is the 5th highest of 8, against a peer median of +98.0%.
- Stock-based compensation amounts to 14.1% of revenue for FRX.TO, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.67M USD | +143.3% | +84.7% | — | |
| LTM Mar 2026 | $7.23M USD | +54.8% | +18.6% | 14.1% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $5.55M USD | +98.0% | +9.0% | 29.6% |
| LTM Mar 2026 | CA$5.06M CAD | +220.3% | -44.8% | 1.6% | |
| LTM Mar 2026 | $4.38M USD | -55.0% | -25.6% | 1.7% | |
| LTM Mar 2026 | CA$3.45M CAD | -36.6% | — | 1.3% | |
| LTM Mar 2026 | $246K USD | +228.0% | — | 0.1% | |
| LTM Apr 2026 | CA$0 CAD | -100.0% | — | — | |
| Peer median (excluding FRX.TO) | — | +98.0% | -8.3% | 1.6% | |
Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Depreciation & Amortization | 0 | 0 | 0 | 800K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.02M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (932K) | 1.1M | (6.78M) | 16.94M | (12.04M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.44M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.28M) |
| Accounts Payables | (794K) | 1.61M | 1.39M | (537K) | 1.39M |
| Other Working Capital | (138K) | 1.61M | 683K | 24.77M | 282K |
| Other Non-Cash Items | 307K | 466K | 326K | 4.61M | (26.45K) |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 19.94M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22K) | 797K | 1.64M | (439K) | (190.27K) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 25.01M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (1.5M) |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 8.83M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (14.67M) |
Fennec Pharmaceuticals Inc.
TSX:FRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$19.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.